Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) COO Sells $578,426.88 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Free Report) COO Patrick O’brien sold 29,184 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $578,426.88. Following the sale, the chief operating officer now owns 535,201 shares of the company’s stock, valued at approximately $10,607,683.82. This represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $19.75 on Friday. The firm’s 50 day moving average price is $21.05 and its 200-day moving average price is $22.53. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The stock has a market capitalization of $2.46 billion, a PE ratio of -3.93 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $17.05 and a twelve month high of $39.83.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Citigroup reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $43.33.

Check Out Our Latest Stock Report on ARWR

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Nordea Investment Management AB increased its stake in shares of Arrowhead Pharmaceuticals by 6.3% in the 4th quarter. Nordea Investment Management AB now owns 132,188 shares of the biotechnology company’s stock worth $2,463,000 after purchasing an additional 7,776 shares in the last quarter. Franklin Resources Inc. increased its position in Arrowhead Pharmaceuticals by 9.4% in the third quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock worth $373,000 after buying an additional 1,658 shares in the last quarter. World Investment Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock worth $371,000 after buying an additional 700 shares during the period. Geode Capital Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after buying an additional 26,171 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $345,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Featured Stories

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.